ALKERMES PLC

Alkermes insider Todd sells 7,576 shares at $49.19—routine plan trade, no distress, but a key signal to watch as pipeline milestones loom.

Alkermes CEO Jackson Blair Curtis buys 93k shares & secures 124k options, signaling confidence in the company’s pipeline & long‑term upside despite recent insider sales.

Wright Christopher I sells 2,000 Alkermes shares at $45.10—an insider move that offers insight into the company’s strong fundamentals and future prospects.

Alkermes insider sale: EVP David Gaffin sells 2,034 shares at $34.57. Routine move, no market shock—yet signals active management amid strong clinical progress.

Alkermes insider trades reveal steady confidence: EVP Craig Hopkinson’s April 1 purchase amid a 23 % rally shows disciplined buying, hinting at long‑term faith in the company’s CNS and infectious disease pipeline.

Alkermes CFO’s $97k equity grant signals top‑level confidence—executive incentives align with shareholder upside amid a volatile biotech market.

Alkermes insider trading shows mixed buying and selling, suggesting leadership confidence amid earnings volatility and a potential rebound in the biopharma’s CNS pipeline.

Alkermes insider activity: EVP David Gaffin’s latest share trades reveal cautious confidence amid the company’s Avadel acquisition and potential upside.

Alkermes insider buying signals management confidence amid Avadel acquisition; learn what Parisi Samuel Joseph’s trades mean for investors.

Alkermes insider buys 5,000 shares at $19.34 under a 10‑b‑plan, betting on a short‑term rise as the company’s Breakthrough Therapy for alixorexton gains momentum.